Industry News
19 Approved ADCs Worldwide: The Ultimate …
As of 2025, a total of 19 ADC drugs have been approved globally.
List of FDA Approved PEGylated Drugs Up t…
History of PEGylated drugs, list of FDA approved PEGylated drugs, advantages and challenges of PEGylation.
Oligonucleotide Drug Delivery: Advances a…
Learn how GalNAc, LNP, AOC, CPP, and exosome-based systems are reshaping oligonucleotide drug delivery for precise, tissue-targeted therapies.
Tetrahydrocurcumin and its Therapeutic Po…
Tetrahydrocurcumin (THC), a major color-free metabolite of curcumin formed by reducing its central double bonds, displays better bioavailability and different biological activity and molecula…
CLDN18.2-Targeted ADCs: A Promising Break…
As of 2025, the global R&D landscape for CLDN18.2-targeted antibody-drug conjugates (ADCs) is expanding rapidly, with multiple candidates entering mid- to late-stage clinical trials.
Aficamten: Novel Cardiac Myosin Inhibitor…
Aficamten is an investigational, oral, small molecule cardiac myosin inhibitor. It was designed to reduce the hypercontractility associated with Hypertrophic cardiomyopathy (HCM)
HER2 ADCs 2025: Complete Guide to Approve…
To date, there are 19 ADCs approved worldwide. Among them, four HER2-targeting ADCs have received regulatory approval worldwide.
Comprehensive Overview of Common Chemical…
Discover a comprehensive guide to common sunscreen ingredients, their UV protection ranges, stability, safety, and regulatory approvals.
Vepdegestrant NDA Accepted: A Milestone f…
On August 8, 2025, Arvinas and Pfizer announced that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for vepdegestrant (ARV-471).
FDA Approves 16 Innovative Drugs in H1 20…
In H1 2025, the FDA approved 16 innovative drugs, including breakthroughs in antibody-drug conjugates (ADCs) and novel treatments for cancer, pain, infections, and rare diseases.
sales@huatengusa.com
+86 0731 89916275